All News

price%20of%20pills.jpg

Why Patients Don't Take Medicines

d CDC

About 60% of adults aged 18 and over reported taking at least one prescription medication in 2021, with 36% reporting taking three or more. Out-of-pocket costs on retail drugs rose 4.8% to $63 billion in 2021.

Read Article
FDA,approved,stamp,blue

FDA Approves Colchicine for CV Prevention

d Jack Cush, MD

The FDA has approved colchicine (Lodoco) for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with such an indication.

Read Article
Biologic.choice.MD_.jpeg (keep)

Treatment Sequences Define Subphenotypes in RA Patients

d Jack Cush, MD

An analysis of a large rheumatoid arthritis cohort sheds light on biologic disease-modifying anti-rheumatic drugs (bDMARDs) clustering that may be used in management, as certain clusters of b/tsDMARD correlated with disease activity over time. 

Read Article
cost.price_.drugs_.pills_.jpg

Are bDMARDs, tsDMARDs and biosimilar DMARDs cost effective?

d Jack Cush, MD

Treatment advances with new biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) have proven efficacy and safety; but does their increased cost yield commensurate benefits in patients with rheumatoid arthritis (RA) and high disease activity?

Read Article
Abatacept Safety Outcomes Across 7 European Registries A multinational registry analysis of RA receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy. https://t.co/CVeAV0ZXA8 https://t.co/A8McLt0rSl

Links:

Dr. John Cush RheumNow ( View Tweet)
2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis These included 5 overarching principles & 10 recos on the role of imaging in making a diagnosis, monitoring, predicting, guiding therapy, and patient education in CiA. https://t.co/OaRBNfhNCJ https://t.co/gF9QFDYTsu

Links:

Dr. John Cush RheumNow ( View Tweet)
Uncertainty can be worrisome. When uncertainty lies ahead, optimism and preparation are your best navigators. Im an optimist. https://t.co/JNzWJFMEfV https://t.co/ltIdy6hNqn

Links:

Dr. John Cush RheumNow ( View Tweet)
Medicare and Commercial claims analysis shows 1 #RA pts at risk for H Zoster 2 RA + HZ = more Hospitalizations & ED visits, esp in 30d after HZ 3 Higher total costsalso higher in month after HZ https://t.co/gFlsLDIxVB https://t.co/733W3Kv3WC

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 28,360 #PsA pts shows blacks have signif more HTN (59 v 52%), DM (31 v 23%), obesity (47 v 30%), gout (12 v 8%); while whites have more cancer (20 v 16%), anxiety (28 v 23%) & OP (14 v 12). Rx (NSAIDs, TNFi, DMARDs) also unequal by race. https://t.co/Ok7vhTdS8g https://t.co/ozFIg9HNuy

Links:

Dr. John Cush RheumNow ( View Tweet)
Arborviral infx w/ rituximab? 21 RTX pts dx w/ arboviral neuroinvasive Dz, (encephalitis, acute flaccid myelitis); 79% died. B cell depletion impairs immunity & spread of West Nile Virus, serologic Ab Dx tests; thus if suspected, order RT-PCR tests https://t.co/yQiXI2IYqd https://t.co/dZX2CQJs0L

Links:

Dr. John Cush RheumNow ( View Tweet)
Small study 57 EGPA pts shows using MTX or AZA to be equipotent as 1st or 2nd line therapy in EGPA. MTX pts used more cumulative steroids (6 g vs 10.7 g @5 yrs) & more AE (66% vs 30%); AZA had fewer asthma/ENT relapses (23% vs 64%, p= 0.04) https://t.co/WZHudojrzk https://t.co/X6xITcQtCw

Links:

Dr. John Cush RheumNow ( View Tweet)
Predictors of DAPSA28 remission in #PsA starting 1st TNF-inhibitor (13 369 bio-naive pts from 13 Euro registries) showed 6 mo remission 25% and 12 retention 63%. Remission predictors: younger age, Dz duration, males (OR 1.85), CRP >10 (OR 1.52) https://t.co/cTefy6xeUB https://t.co/b2Ok6HJgE1

Links:

Dr. John Cush RheumNow ( View Tweet)
HRT for RA? Not Yet Dr. Aurelie Najm discusses OP0268 presented at EULAR 2023 in Milan, Italy. @AurelieRheumo https://t.co/hoyZ2Ezn4G https://t.co/XWfE1RHwpi

Links:

Dr. John Cush RheumNow ( View Tweet)
Abatacept Safety Outcomes Across 7 European Registries A multinational registry analysis of rheumatoid arthritis receiving abatacept has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy. https://t.co/XcOSLTgQVR https://t.co/ZfwAA0baRM

Links:

Dr. John Cush RheumNow ( View Tweet)
2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis These included 5 overarching principles & 10 recommendations on the role of imaging in making a diagnosis, monitoring, predicting, guiding therapy, and patient education in CiA. https://t.co/5WoIm8OPZs https://t.co/xqNxDvuymJ

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s newly launched Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Posters addressing vasculitis, AxSpa and nrAxSpa, and PMR now available. https://t.co/0dV23VPDQH https://t.co/HfKhji40vU

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Should you Assess Rheumatoid Factor Serially? Dr. Jack Cush discusses abstract OP0272 at EULAR 2023 in Milan, Italy. https://t.co/5e4SiPGDUM https://t.co/CzE597Auwg

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: De Novo Renal Nephritis Flares During Belimumab Trials Drs. Yuz Yusof and Iaonnis Parodis discuss abstract POS1156 at EULAR 2023 in Milan, Italy. https://t.co/XLzDF2VZ7Q https://t.co/iE16Ag3Rsu

Links:

Dr. John Cush RheumNow ( View Tweet)
How Often Do You Monitor MTX? Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow including new drug approval, a new SpA variant and new rules for methotrexate (MTX) monitoring and depression screening. https://t.co/niPFjQTenh https://t.co/JyL8t6EexT

Links:

Dr. John Cush RheumNow ( View Tweet)
Pediatric Rheumatologist Loan assistance repayment program from HSRA. A loan assistance of up to $100,000 to eligible pediatric medical subspecialists in exchange for a 3-year, full-time service commitment at an approved facility in an underserved area https://t.co/6oFkEEKAY9

Links:

Dr. John Cush RheumNow ( View Tweet)

×